X
GO

COVID-19 Monoclonal Antibody Therapeutics Information for Providers

Recently, bamlanvimab and casirivimab/imdevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa. 

 

For long-term care facilities, FQHCs, dialysis centers, home infusion providers, and correctional facilities:

HHS/ASPR has implemented a new federal program for the allocation of monoclonal antibodies called the Special Projects for Equitable and Efficient Distribution (SPEED). The goal of SPEED is to assist states in identifying non-hospital/non-hospital affiliated facilities that serve priority populations and allocating mAbs for administration to their patients.  It should be noted that SPEED is separate yet complementary to the state-based mAb allocation system. SPEED is conducted in partnership with stakeholder/industry associations who assist with educating members (and non-members) about the mAb and identifying those who are able and willing to administer these infusions. Membership in participating associations is not required for participation as a SPEED site. For additional information about SPEED, visit https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/SPEED.aspx

 

Sites that are interested in participating in SPEED can submit a request for mAbs.

 

For Hospitals and Clinics:

The Iowa Department of Public Health receives state allocations every two weeks (previous weekly) for bamlanivimab and casirivimab/imdevimab and further allocates these medications to hospitals and other healthcare provider settings. AmerisourceBergen is responsible for distribution and shipment of medications directly to hospitals. For more information on the allocation and distribution process, see the bamlanivimab distribution overview and casirivimab/imdevimab distribution overview.

 

Contact for General Questions    Request for mAbs    mAb Site Locator

 

Resources

General Resources

 

Bamlanivimab (Eli Lilly)

 

Casirivimab/Imdevimab (Regeneron)

 

Billing and Coding